



Institutional Biosafety Committee Minutes

Date: Wednesday, September 17, 2025

Time: 9:30 AM

Location: Zoom Meeting

MEMBERS IN ATTENDANCE

Busch, Robert H
Carroll, Ann M.
Finkernagel, Scott W.
Kaminsky, Stephen M.
Lieggi, Christine
McGuinn, Catherine
Otero, Miguel
Repik, Gabrielle
Schnappinger, Dirk
Wagner, John A.
Willis, Dianna E.

MEMBERS ABSENT

Brown, Anthony

STAFF

Gonzalez Russi, Sabrina
Lejb, Katarzyna

Meeting Minutes for Approval

- August 20, 2025

System error acknowledged and corrected. No other issues were raised, and the committee approved the minutes from August 20, 2025.

Safety Officer Report

- NIH new biosafety modernization initiative

New Business

- In Memoriam- Dr. Gross

Conflicts of Interest Disclosure:

No member of the IBC may participate in the review of any project in which the IBC member is an investigator, has a financial conflict of interest, or has any other interest which has an adverse impact on the IBC member's ability to exercise independent judgment. Under such circumstances, the IBC member shall not be present during IBC deliberations, except to provide information requested by the IBC. Each member of the IBC shall respect and preserve the confidentiality of information he/she receives as a member of the IBC, and shall use, discuss, and/or disclose such information only for purposes related to deliberations or other assigned business of the IBC.

- Dr. Kaminsky reported a Conflict of Interest with Dr. Kelly's registration listed on the agenda.

Laboratory Safety Registrations - 2-Year Renewals

Record Number: 19-0432

PI Name: Miklos Toth

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no changes associated with this renewal. The reviewer noted that the research description includes DNMT3a overexpression, however this is not included in the biological/microbiological microorganism tracking table. No other issues were raised. With the administrative change of adding DNMT3a overexpression to the biological/microbiological microorganism tracking table, the reviewer recommended approval of AAV at ABSL-1 and Lentivirus at ABSL-2/BSL-2.

Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adeno-Associated Virus (AAV)		AAV 1-12	Replication Incompetent/Deficient	N/A	In Vivo	In vivo	synaptophysin, channel rhodopsin, halorhodopsin, archaerhodopsin, DRE ADDs, GFP, YFP, mCherry, mCitrine, DNMT3a	Bacteria ~ Human ~ Jellyfish ~ Murine ~ Other/ Bacteria	Marker/ Reporter ~ Other/ AAV is interjected into targeted location in the brain.	Direct inject into In vivo model ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest	ABSL-1	NIH Applicable	Section II I-D-4
Lentivirus [Retroviridae/ Lentiviridae]		pLenti-P3 A, B, C(A BM), pLentiRNA-GFP (A BM)	Attenuated ~ Replication Incompetent/Deficient	293T	Both	In vivo	si-RNA for neurexin I and II	Bacteria ~ Other/ Bacteria	Gene Expression Regulators	Direct inject into In vivo model ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III -D-3 ~ Section III- D-4

Record Number: 19-0455

PI Name: Manikkam Suthanthiran

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no changes associated with this renewal. No issues were raised. The reviewer recommended approval at previously assigned biosafety levels.

Decision: Approved

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	Human Renal Transplant Patient samples	SARS-CoV-2	Replication Competent	In Vitro	Other	BSL-2+	Not rDNA	

Record Number: 19-0506

PI Name: Baolin Wang

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol, noted no recombinant DNA will be used to generate gene knockout model and the removal of transgenic model. No issues were raised. The reviewer recommended approval at previously assigned biosafety levels and E. Coli at BSL-2.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/genome family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviral/Lentiviral]		CRISPR v2, pLenti-CMV-puro	Replication Incompetent/Deficient	HEK293, NIH3T3, mouse fibroblasts	In Vitro	In vivo	cas 9, Gli2, gli3, Smo, Ptc, Sufu, Dzip1, Dzip1L, Ftm, T a3, ciliary genes, puromycin, neomycin	Murine	Gene Expression Regulators ~ Marker/Reporter ~ Oncogenic Gene Sequences	Create virions ~ Express/Upregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line ~ Transfect cells	BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Murine leukemia virus [Viral vector/In vivo retrovirus]		pLNCX	Replication Incompetent/Deficient	E. coli, HEK293, NIH3T3	In Vitro	In vivo	Gli2, gli3, Smo, Ptc, Sufu, Dzip1, Ftm, Dzip1L, T a3, ciliary genes, neomycin	Murine	Antibiotic Resistance ~ Gene Expression Regulators ~ Oncogenic Gene Sequences	Create virions ~ Repress/Downregulate gene of interest ~ Transfect cell line	BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Escherichia coli [K12]		Non-replicative lentiviral constructs for hedgehog signaling components and ciliary genes such as Ptc1, Smo, Gli 2, Gli3, Dzip1, Dzip1L, etc.	Replication Incompetent/Deficient	293 cells	In Vitro	In vivo	Hedgehog signaling pathway components and ciliary related genes such as Ptc1, Smo, Gli2, Gli 3, Dzip1, Dzip1L, etc.	Murine	Antibiotic Resistance ~ Gene Expression Regulators ~ Oncogenic Gene Sequences	Create virions ~ Express/Upregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-2

Record Number: 21-0111

PI Name: James Kelly

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no significant changes associated with this renewal. No issues were raised. The reviewer recommended keeping approval of AAV at ABSL-1 for in vivo work, however the lab work should be BSL-2 because of transfection work with HEK293 cells.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/genome family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
------------------------------------	--------------------------	---------------------------------------	----------------------------------	---	----------------------	---------------------------	--	---------------------------------------	--	--------------------------------------	-----------------------------	----------------------	---------------------------

Adeno-Associated Virus (AAV)		AAV2	Replication Incompetent/Deficient	N/A (We will purchase recombinant reporter/control virus from Vector Biol abs and determine transfect on efficiency in HEK293 cells using the reporter gene)	Both	Human	Beta-galactosidase (LacZ) and/or green fluorescent protein (GFP)	Bacteria~ Jellyfish	Marker/Reporter	Express/Upregulate gene of interest ~ Transfect cell line	ABSL-1~ BSL-2	NIH Applicable	Section II I-D-4
------------------------------	--	------	-----------------------------------	--	------	-------	--	---------------------	-----------------	---	---------------	----------------	------------------

Record Number: 22-0013

PI Name: Sarah Cheal

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no changes associated with this renewal. No issues were raised. The reviewer recommended keeping approval at previously assigned biosafety levels.

Decision: Approved

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism f or Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Salmonella [Typhimurium]		Salmonella 1402 8S (delta mshB)	Attenuated	Both	Conduct Multiplicity of infection (MOI) studies ~ Culturing ~ Introduction into In vivo model	ABSL-2 ~ BSL-2	Not rDNA	

Record Number: 22-0075

PI Name: Mark Bustoros

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no changes associated with this renewal. No issues were raised. The reviewer recommended keeping approval at previously assigned biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level (s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		Addgene: pMD2.G- VSV-G envelope expressing plasmid psPAX2-2nd generation lentiviral packaging plasmid, pLKO5.sgRNA.E FS.GFP (addgene #57822) and pLKO5.sgRNA.E FS.PAC (addgene #57825)	Attenuated ~ Replication Incompetent/Deficient	Multiple Myeloma cell lines	Both	In vivo ~ Human	SETD2 is considered an oncogene and transcription regulator.	Human ~ Murine	Gene Expression Regulators ~ Oncogenic Gene Sequences	Create virions ~ Direct inject into In vivo model ~ Express/Upregulate gene of interest ~ Repress/Down regulate gene of interest~ Transfect cells	ABSL-2+ ~ BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III- D-3 ~ Section III-D-4

Record Number: 23-0014

PI Name: Benedict Law

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted no changes associated with this renewal. No issues were raised. The reviewer recommended keeping approval at previously assigned biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		T2A-RFP-IRES-Puro Lentivirus LPP-PLUM-Lv	Replication Incompetent/Deficient ~ Unknown	N/A-commercial sources (Biosetta and GeneCopeia).	Both	In vivo ~ Human	Luciferase (FLuc), red fluorescent protein (RFP), puromycin resistance gene (Puro), PLUM, CMV	Human ~ Murine	Antibiotic Resistance ~ Marker/Reporter	Express/Upregulate gene of interest ~ Transfect cell line ~ Transfect cells / introduce into in vivo model	ABSL-1 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III- D-3 ~ Section III-D-4

Record Number: 23-0075

PI Name: Michelle S. Bradbury

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and noted minor changes associated with this renewal. The reviewer requested clarification regarding which vectors are being utilized and enhanced descriptions are required for the various model plans. Further clarification is requested on whether mucin or PDGF-HA are cytokines. No other issues were raised. The reviewer recommended the renewal be tabled and re-reviewed after a more detailed description is provided.

Decision: Registration approval tabled

Record Number: 24-0117

PI Name: Logan Grosenick

Submission Type: Renewal

Notes: The assigned IBC member reviewed the lab protocol and the change of adding a serotype of AAV. No issues were raised. The reviewer recommended keeping approval at previously assigned biosafety levels.

Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Rabies virus [Rhabdoviridae/Lyssavirus]		SAD-deltaGmCherry, SAD-deltaGmCherry (EnvA)	Attenuated ~ Replication Incompetent/Deficient	BHK-B19G	In Vivo	In vivo	mCherry rabies for stereotactic injections	Jellyfish	Marker/Reporter	Direct inject into in vivo model ~ Express/Upregulate gene of interest	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4
Adeno-Associated Virus (AAV)		AAV serotypes 1, 2, 5, 9	Replication Incompetent/Deficient	N/A purchased	In Vivo	In vivo	channel rhodopsin GCaMP6s	Murine	Other	Direct inject into in vivo model ~ Express/Upregulate gene of interest	ABSL-1	NIH Applicable	Section II I-D-4 ~ Section III-F-6
Canine Adenovirus [CAV-1, CAV-2]		CAV-1, CAV-2	Attenuated ~ Replication Incompetent/Deficient	N/A-purchased	In Vivo	In vivo	channel rhodopsin GCaMP6s	Murine	Other	Direct inject into in vivo model ~ Express/Upregulate gene of interest	ABSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4 ~ Section III-F-6

Acknowledgement of Laboratory Safety Registrations: No IBC-Applicable Work Conducted

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0697	Jenny Zhaoying Xiang	Lab Registration - Renewal
21-0032	Gene Kim	Lab Registration - Renewal
22-0063	Moustafa Gabr	Lab Registration - Renewal
24-0027	Jack Levy	Lab Registration - Renewal
24-0039	Vanessa Bellat	Lab Registration - Renewal

Laboratory Safety Registrations: Exempt

Record Number	PI Name	Laboratory Safety Registration Submission Type
25-0066	Kaavya Krishna Kumar	Lab Registration - Initial

Acknowledgment of Closed Laboratory Safety Registrations

Record Number	PI Name
19-0502	Elena Piskounova
19-0503	Harold E. Varmus

The meeting adjourned at 10:14 AM.